Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 13 of 13 for “"4-1BB"”.
-
4-1BB-Mediated signal transduction
This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).
-
Activating The 4-1Bb Pathway For The Expansion of Tumor-Infiltrating Lymphocytes For Adoptive T-Cell Therapy For Metastatic Melanoma Patients
… T-cell therapy by understanding the role of 4-1BB/CD137 co-stimulation during the expansion of the tumor-infiltrating lymphocytes (TIL). Adoptive T-cell therapy using TIL is a promising therapy for late stage melanoma patients, resulting in a 50% response rate and durable long-term survival in …
-
Tumor Immunotherapy: Mechanisms of Acquired Resistance and Characterization of Immune Related to xicities
… targeting the T cell co-stimulatory receptor 4-1BB (CD137) are among the most effective immunotherapeutic agents across pre-clinical cancer models. Clinical development of these agents, however, has been hampered by dose-limiting liver toxicity. Lack of knowledge of the mechanisms underlying …
-
Novel immunotherapy for paediatric cancers
… removing IgG1 Fc and incorporation of CD28 or 4-1BB co-stimulatory domains improve the in vivo potency of PB-CARs. At diminishing doses, 4-1BB co-stimulation led to greater potency and persistence of CART cells compared to CD28. These pre-clinical data provided the basis for testing PB …
-
The State of T Cell Immunity against Influenza Virus in Humans and Exploration of Potential Strategies to Enhance Cell-Mediated Protection from Influenza Infection
… evaluated a murine prime/boost model using the 4-1BB costimulatory pathway to induce persisting CD8 T cell responses. 4-1BBL signals during boost immunization resulted in superior numbers and function of persisting influenza-specific CD8 T cells. Since TRAF1, an adaptor molecule for 4-1BB …
-
Memory Potential, Molecular Characterization, and Translational Applications of The Novel Theo/Tceo T Cell Phenotype
… Targeting the T cell co-stimulatory receptor 4-1BB with agonist antibodies engenders strong antitumor responses in multiple murine tumor models, in part by expanding the proliferative capacity, survival, and cytotoxicity of T cells within the tumor microenvironment. We have previously shown that …
-
T Cell Exhaustion in Glioblastoma
… in patients with GBM. In Chapter 5 we explore 4-1BB agonism as a means to prevent T cell exhaustion and thus sensitize GBM to immunotherapeutic strategies. In Chapter 6 we describe the mechanism driving T cell exhaustion and reveal a novel mechanism by which T cell based immunotherapies may …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… CD19-CD79b CAR was composed of CD19 CAR with 4-1BB co-stimulatory domain and CD79b CAR with OX-40 linked by T2A self-cleavable peptide. High transduction efficiency of dual CD19-CD79b CAR was achieved and stable dual CAR expression was observed in both CD4+ and CD8+ T cell subsets. My method of …
-
Bringing Til Therapy Beyond Melanoma: Advancing The Treatment of Advanced Pancreatic and Ovarian Cancers
… consisting of a CD3 stimulation, an agonistic 4-1BB mAb, and high-dose IL-2. Additionally, these results show that TIL ACT for PDAC and OvCa is viable regardless of primary or metastatic site and regardless of prior chemotherapy. Furthermore, given the difficulty of treating PDAC, single-cell RNA …
-
Development of a canine model to evaluate CAR-T cell subsets
… more costimulatory domains, often CD28 and/or 4-1BB. Mechanisms of relapse and treatment failure for CAR-T cell therapy are related to loss of CAR-T targeting (e.g. target antigen loss) and dysfunction of CAR-T cells (e.g. immunosuppressive microenvironment). These mechanisms of resistance to …
-
Collagen Anchoring Agonist Antibodies for Cancer Immunotherapy
… vivo, we tested agonist antibodies targeting 4-1BB and CD28 fused to the collagen binding domain LAIR (α4-1BB- LAIR and αCD28-LAIR, respectively), in a range of monotherapy and combination therapies. We observed that while combination treatment of α4-1BB-LAIR with an antitumor antibody (TA99) …
-
Enhancing Adoptive Cell Therapy By Augmenting Fitness and Anti-Tumor Function of Tumor-Infiltrating Lymphocytes
… using an agonistic CD3 (TCR stimulation), 4-1BB (co-stimulation) antibodies and IL-2 (cytokine support), an approach referred to as “TIL 3.0”. We demonstrated the feasibility of robustly expanding a T-cell repertoire recapitulating the clonal hierarchy of the T cells in the NSCLC tumor, …
-
Tolerizing Effects of Soluble CD137 on the CD137-CD137L Signaling Axis for Exploitation as a Therapeutic in Type 1 Diabetes
Las enfermedades autoinmunes (EAI) representan un desafío mayor y creciente para la salud global, siendo la diabetes tipo 1 (DT1) un ejemplo destacado. Estas enfermedades se caracterizan por una falla en la tolerancia inmunológica, lo que da lugar a la activación de células T patógenas que atacan a …